TriangleNCT02354586 · OUTCOME
Number of Participants With Abnormality in Vital Signs
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- Not reported
- Unit
- Not reported
- Interval / dispersion
- Not reported
- Time frame
- Up to 3 years
What was measured
Number of participants with abnormality in vital signs were planned to be analyzed.
Analysis population: Safety Population. This was an other pre-specified outcome measure. Data will not be analyzed and reported.
Groups in this outcome
Niraparib 300 mg
Participants received Niraparib (300 milligram \[mg\], taken as 3 capsules of 100 mg once daily \[QD\]) orally beginning on Day 1 of every cycle (28 days) until treatment discontinuation.
| Group | Source count |
|---|---|
| Niraparib 300 mg | 0 |
Reported measurements
No numerical measurement classes were posted for this outcome. Missing is not zero.
Complete source fields
- denoms
- counts
- group Id
- OG000
- value
- 0
- units
- Participants
- description
- Number of participants with abnormality in vital signs were planned to be analyzed.
- groups
- description
- Participants received Niraparib (300 milligram \[mg\], taken as 3 capsules of 100 mg once daily \[QD\]) orally beginning on Day 1 of every cycle (28 days) until treatment discontinuation.
- id
- OG000
- title
- Niraparib 300 mg
- population Description
- Safety Population. This was an other pre-specified outcome measure. Data will not be analyzed and reported.
- reporting Status
- POSTED
- time Frame
- Up to 3 years
- title
- Number of Participants With Abnormality in Vital Signs
- type
- OTHER_PRE_SPECIFIED
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice